Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (641-650 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American Heart Association|February 21, 2023
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-ITBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Journal of Thrombosis and Haemostasis : JTH|July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or olderWalter Ageno, Renato D Lopes, Mark Goldin, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
American Heart Journal|October 3, 2002
Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) studyMeyer Elbaz, Elyes El Mokhtar, Khalifé Khalifé, et al.
European Heart Journal|December 18, 2021
Alirocumab after acute coronary syndrome in patients with a history of heart failureHarvey D White, Gregory G Schwartz, Michael Szarek, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Clinical Cardiology|August 27, 2016
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With StentingChristopher P Cannon, Savion Gropper, Deepak L Bhatt, et al.
Nature Reviews. Disease Primers|June 8, 2019
ST-segment elevation myocardial infarctionBirgit Vogel, Bimmer E Claessen, Suzanne V Arnold, et al.
Pageof 97

Showing results (641-650 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American Heart Association|February 21, 2023
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-ITBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Journal of Thrombosis and Haemostasis : JTH|July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or olderWalter Ageno, Renato D Lopes, Mark Goldin, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
American Heart Journal|October 3, 2002
Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) studyMeyer Elbaz, Elyes El Mokhtar, Khalifé Khalifé, et al.
European Heart Journal|December 18, 2021
Alirocumab after acute coronary syndrome in patients with a history of heart failureHarvey D White, Gregory G Schwartz, Michael Szarek, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Clinical Cardiology|August 27, 2016
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With StentingChristopher P Cannon, Savion Gropper, Deepak L Bhatt, et al.
Nature Reviews. Disease Primers|June 8, 2019
ST-segment elevation myocardial infarctionBirgit Vogel, Bimmer E Claessen, Suzanne V Arnold, et al.
Pageof 97